Testosterone has been in clinical use for over 60 years, yet the choice of preparations was very limited until recently and substitution therapy of hypogonadal patients was not ideal. During the last several years a number of new injectable, transdermal and buccal preparations have become available, and as clinical experience accumulates the advantages and disadvantages of the various preparations become evident.
Physicians treating hypogonadal men need in-depth knowledge of the various testosterone preparations in order to inform the patients adequately and to select with them the best preparation for the purpose of the individual patient. The focus of this symposium is on testosterone undecanoate, the new long-acting injectable testosterone preparation (Nebido®). The four presentations and the discussion will familiarize the clinician with the pros and cons of this new form of testosterone substitution.
Eberhardt Nieschlag, MD
read CV | view presentation | read transcript
Michael Zitzmann, MD, PhD & Eberhardt Nieschlag, MD
read CV | view presentation | read transcript
Alvaro Morales, MD, FRCSC, FACS
read CV | view presentation | read transcript
Markus Schubert, MD
read CV | view presentation | read transcript
Aksam A. Yassin, MD, PhD
read CV | view presentation | read transcript
Eberhardt Nieschlag, MD; Alvaro Morales, MD, FRCSC, FACS; Markus Schubert, MD; Aksam A. Yassin, MD, PhD & Michael Zitzmann, MD, PhD
view presentation | read transcript
Copyright © 2006 ISSAM